Literature DB >> 32833568

Lessons Learned from Caring for Patients with COVID-19 at the End of Life.

Anirudh Rao1,2, Anne Kelemen1,2.   

Abstract

Over 140,000 people in the United States have died as a result of infection with COVID-19. These patients have varying death experiences based on their location of death, the availability and utilization of various medical technologies, the amount of strain on the local health care system, the involvement of specialist palliative care (PC) teams, and access to essential medications to alleviate symptoms at the end of life. The objective of this report is to describe the death experiences of four patients cared for in an urban academic medical center who received very different degrees of medical interventions and to examine the interventions of our interdisciplinary PC team. We conclude that PC teams must adapt to this new landscape by creating best practices for ensuring adequate symptom control, modifying approaches for withdrawal of life-sustaining medical technologies, and gaining facility with communication through teleconferencing platforms to meet the challenge of alleviating suffering for people dying from COVID-19.

Entities:  

Keywords:  COVID-19; end-of-life care; withdrawal of life-sustaining medical treatments

Year:  2020        PMID: 32833568     DOI: 10.1089/jpm.2020.0251

Source DB:  PubMed          Journal:  J Palliat Med        ISSN: 1557-7740            Impact factor:   2.947


  2 in total

1.  Optimal timing for hospice-shared care initiation in terminal cancer patients.

Authors:  Yan-Mei Dai; Ya-Ting Huang; Min-Yu Lai; Hsueh-Erh Liu; Chih-Chung Shiao
Journal:  Support Care Cancer       Date:  2021-05-20       Impact factor: 3.603

2.  Pandemic impact on patients with advanced non-COVID-19 illness and their family carers receiving specialised palliative home care: a qualitative study.

Authors:  Stina Nyblom; Inger Benkel; Linnéa Carling; Elisabet Löfdahl; Ulla Molander; Joakim Öhlén
Journal:  BMJ Open       Date:  2022-05-19       Impact factor: 3.006

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.